MR

Marinus Pharmaceuticals IncNASDAQ MRNS Stock Report

Last reporting period 30 Jun, 2024

Updated 18 Nov, 2024

Last price

Market cap $B

0.105

Micro

Exchange

XNAS - Nasdaq

MRNS Stock Analysis

MR

Uncovered

Marinus Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-32/100

Low score

Market cap $B

0.105

Dividend yield

Shares outstanding

49.665 B

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. The company is headquartered in Radnor, Pennsylvania and currently employs 151 full-time employees. The company went IPO on 2014-07-31. The firm's commercial product, ZTALMY (ganaxolone) oral suspension CV for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase III trials in tuberous sclerosis complex and refractory status epilepticus. The firm's ganaxolone is a neuroactive steroid gamma-aminobutyric acid type A (GABAA) receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. The Company’s ganaxolone is also being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.

View Section: Eyestock Rating